Prostate Cancer Quarterly Benchmarks Report

Fiscal Year 2013 3rd Quarter Report

Jurisdiction/Program: ALL

Sponsor: CRF

| | | | · | | | 1 | | |
|---|-----|--|-----------|------------|------------|------------|----------|------------|
| | | | Period: | 7/1-9/30 | 10/1-12/31 | 1/1-3/31 | 4/1-6/30 | 7/1/-6/30 |
| | | | Run Date: | 01/09/2013 | 04/03/2013 | 07/10/2013 | | |
| Category | No. | Indicator | Standard | FY13 1Q | FY13 2Q | FY13 3Q | FY13 4Q | FY13 Total |
| Screening Priority Population | 1 | Percent of prostate cancer screenngs with both PSA and DRE | ≥80% | 100.0 | No Data | No Data | | |
| Case Management Among Program-eligible Clients | 2 | Percent of prostate cancer screenings* with abnormal findings/needs further evaluation to rule out cancer with a diagnosis status of 'Complete' | ≥80% | No Data | No Data | No Data | | |
| | 3 | Percent of prostate cancer screenings* with abnormal findings/needs further evaluation to rule out cancer with date of diagnosis within 90 days of screening among those with diagnosis status of 'Complete' | ≥80% | No Data | No Data | No Data | | |
| | 4 | Percent of prostate cancers diagnosed with treatment started | ≥80% | 100.0 | 0.0 | 0.0 | | |
| | 5 | Percent of prostate cancers with treatment started within 60 days of diagnosis among those who started treatment | ≥80% | 0.0 | No Data | No Data | | |
| | 6 | Percent of prostate cancers with stage information among clients diagnosed with cancer who had surgery | ≥80% | 0.0 | 0.0 | 0.0 | | |
| Notification | 7 | Percent of PSA results received by the program within 28 days of test | ≥80% | 100.0 | No Data | No Data | | |
| | 8 | Percent of men ever notified of screening* results by program | ≥95% | 100.0 | No Data | No Data | | |
| | 9 | Percent of men with abnormal findings/needs further evaluation to rule out cancer, were notifed of results, and were notified by program within 7 days of when screening ^A results received by program | ≥80% | 100.0 | No Data | No Data | | |

*Screening means screened with Prostate Specific Antigen (PSA) and/or Digital Rectal Exam (DRE) *Screening means screened with Prostate Specific Antigen (PSA) or PSA and Digital Rectal Exam (DRE)